KappaMab

N/A

Report date: 2024/11/29 14:17:08

Base Information

Drug NameKappaMab
Drug Alias NameMDX-1097IST-1097
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionNatural killer cells stimulantsKappa Myeloma antigen inhibitors
TargetsKappa Myeloma antigen
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesImmune Pharmaceuticals IncMedarex Inc
China Registration ClassN/A

Develop Information

Active CompaniesLonzaHaemalogix Pty LtdImmune Pharmaceuticals Inc +[4] 
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A